

Remarks

Claims 1 and 6 have been amended to delete -CH₂-CH₂- from the definition of A. In addition, claims 21-30 have been cancelled. Consequently, no new matter has been added as a consequence of this amendment.

Pursuant to the outstanding Office Action, claims 1 and 6 stand rejected under 35 USC 102(b) as being anticipated by US Patent 4,248,877 (Rissi et al). In addition, claims 21-30 stand rejected under 35 USC 112, second paragraph as being indefinite. Claims 2-5, 12-16 and 32-36 are objected to as being dependent on a rejected base claim; while claims 7-11, 17-20, 31 and 37-40 are allowed.

Rissi et al is directed to compounds useful for treating migraines or depression in animals, which compounds have only an (optionally substituted) phenylethyl or butyrophenone moiety bound to the nitrogen atom of a piperidine ring. Claims 1 and 6 have been amended to delete -CH₂-CH₂- from the definition of A; accordingly, the compounds of the present claimed invention cannot have only a phenylethyl or butyrophenone moiety bound to the nitrogen atom of their piperidyl ring, and therefore such claims (as amended) are no longer anticipated by Rissi et al. Further, Applicants note that there is no suggestion in Rissi et al that the compounds of the present claimed invention would exhibit desirable insecticidal activity. Consequently, it is urged that claims 1 and 6, as amended, are neither anticipated nor suggested by Rissi et al. Further, it is submitted that because claims 1 and 6 are now allowable, the objection to claims 2-5, 12-16 and 32-36 should be withdrawn.

Claims 21-30 have been cancelled. Consequently, the rejection of such claims under 35 USC 112 as being indefinite has been rendered moot.

In light of the foregoing, it is urged that the present claims are now in form for allowance. Reconsideration of the rejections of such claims is therefore respectfully requested.

Respectfully submitted,

August 22, 2011

/John M. Sheehan, Reg. No. 26,065/

John M. Sheehan, Esq.

Reg. No. 26,065

Phone: (215) 299-6966

Correspondence address:

Patent Administrator

FMC Corporation

1735 Market Street

Philadelphia, PA 19103